Magnetic Levitation Makes In Vitro Lung Tissue More Realistic, Could Speed Toxicity Tests
The research is part of an international trend in biomedical engineering to create laboratory techniques for growing tissues that are virtually identical to those found in people's bodies. In the new study, researchers combined four types of cells to replicate tissue from the wall of the bronchiole deep inside the lung.
The research is available online and scheduled to appear in a future issue of the journal Tissue Engineering Part C: Methods.
"One of the unique things about the magnetic levitation technology is that it allows us to move cells around and arrange them the way that we want for a particular types of tissue," said study co-author Tom Killian, professor and department chair of physics and astronomy at Rice. "This is the first time anyone has arranged these four cell types in the same way that they are found in lung tissue."
In vitro laboratory tests have historically been conducted on 2-D cell cultures grown in flat petri dishes, but scientists have become increasingly aware that cells in flat cultures sometimes behave and interact differently than cells that are immersed in 3-D tissue.
Killian and fellow scientists from Rice and the University of Texas MD Anderson Cancer Center co-founded Nano3D Biosciences in 2009 after creating a technology that uses magnetism to levitate and grow 3-D cell cultures. The technology relies on inert, nontoxic magnetic nanoparticles that are inserted into the living cells. Researchers can then use magnets to lift and suspend the cells as they grow and divide.
"Growing realistic lung tissues in vitro is a particular challenge," said study co-author Jane Grande-Allen, professor of bioengineering at Rice. "There are a number of technical obstacles, and scientific funding agencies have placed a particular emphasis on lung tissue because there's a large potential payoff in terms of reducing costs for pharmaceutical and toxicological testing."
Nano3D Biosciences won a Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) in 2011 to create a four-layered lung tissue from endothelial cells, smooth muscle cells, fibroblasts and epithelial cells.
Glauco Souza, the company's chief scientific officer and co-founder, said the project switched into high gear when Rice bioengineering graduate student Hubert Tseng joined the research team as an intern. Tseng was already a student in Grande-Allen's lab, one of Rice's leading laboratories for tissue-engineering research.
"Hubert's and Jane's expertise in tissue engineering was invaluable for tackling this problem," Souza said.
Another collaboration that paid off big was a partnership with a group of undergraduate students at Rice's Oshman Engineering Design Kitchen. The undergraduate team, Cells in 3-D, worked on a magnetic pen that could be used to grab, move and combine magnetized 3-D cell cultures. Souza said Tseng used a version of this tool to create layered bronchiole tissues for this new study.
Tseng said the new tissue resembles native bronchiole tissue more closely than any other tissue yet created in the lab.
"We conducted a number of tests, and the tissue has the same biochemical signature as native tissue," Tseng said. "We also used primary cells rather than engineered cells, which is important for toxicological testing because primary cells provide the closest possible match to native cells."
Souza said bronchiole tissue could solve another problem that's frequently encountered in testing the toxicity of airborne agents.
"With traditional 2-D cultures, it is very difficult to culture cells at the air-liquid interface, which is what you'd prefer for toxicity testing," he said. "With our technology, we can easily levitate the bronchiole tissue to the air-liquid interface so that airborne toxins are exposed to the epithelial layer of the tissue, just as it would occur in the lungs."
Grande-Allen said Tseng and other members of her group have already used the same methods pioneered in the bronchiole study to produce heart valve tissue; Souza said the NSF has awarded the company with a second phase of SBIR funding to further develop the technique for other types of tissue.
Adapted by MNT from original media release